We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Mesh Support for Vaginal Prolapse Repair Is Prone to Erosion

By HospiMedica International staff writers
Posted on 10 Aug 2010
Polypropylene mesh placement during vaginal reconstructive surgery for pelvic organ prolapse appears to do more harm than good, according to a new study.

Researchers at the Washington Hospital Center (WHC, Washington, DC, USA), Rush Medical College (Chicago, IL, USA), and other institutions conducted a double blind, multicenter randomized controlled trial comparing traditional vaginal prolapse surgery (without mesh) with vaginal surgery with mesh. More...
A total of 65 women (mean age 65) with uterovaginal or vaginal prolapse were randomly assigned to either colpopexy with mesh (32 patients) or vaginal colpopexy without mesh (33 patients); women with a uterus also underwent vaginal hysterectomy. The primary outcome measure was objective treatment success at 3 months; secondary outcome measures included quality-of-life (QOL) variables and complication rates.

The results showed that there were no statistically significant baseline differences between the mesh and no-mesh groups with respect to demographics, menopausal status, and race. Analysis of the mesh and no-mesh women also found no difference with respect to overall recurrence. However, there were five (15.6%) vaginal mesh erosions during follow-up. Subjective cure of bulge symptoms was noted in 93.3% of mesh patients and 100% of no-mesh patients. The subjective QOL measurements did not differ between the two groups at baseline or three months postoperatively. The study was published in the August 2010 issue of Obstetrics and Gynecology.

"At 3 months, there is a high vaginal-mesh erosion rate with no difference in overall objective and subjective cure rates,” concluded lead author Cheryl Iglesia, M.D., of WHC, and colleagues. "This study questions the value of additive synthetic polypropylene mesh for prolapse repairs considering that there are no statistically significant differences in subjective or objective cure rates.”

About half of all women between the ages of 50 and 79 have some form of prolapse, and about 11% in the United States will have it surgically treated, with approximately 200,000 procedures for correction of pelvic organ prolapse performed each year in the United States alone.

Related Links:
Washington Hospital Center
Rush Medical College



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Hemostatic Agent
HEMOBLAST Bellows
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.